Oral Diindolylmethane (DIM) for the Treatment of Cervical Dysplasia

• Status: Completed
• Trial end date: 2010-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

To determine if the use of oral Diindolylmethante (DIM), a marketed cruciferous vegetable based dietary supplement (Bioresponse-DIM), is associated with the regression of cervical dysplasia in otherwise healthy women.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: New York Presbyterian Hospital

Criteria

Inclusion Criteria:

• Non pregnant women greater than or equal to 18 years of age able to consent

• CIN II or III confirmed by histology

• Karnofsky performance status >= 80

• No prior treatment for dysplasia in the past 4 months

Exclusion Criteria:

• Incompletely visible lesion

• Diethylstilbestrol (DES) exposure

• HIV seropositive